Organization | University of Milano Bicocca

University of Milano Bicocca Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Milan Italy (1998)

Organization Overview

First Clinical Trial

2010

NCT02136693

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Francesco Gabrielli | San Marcos University | San Marcos University School of Veterinary Medicine | School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos | Universidad Nacional Mayor de San Marcos | University of Milano Bicocca

Active Ingredients

Drugs in Phase 4 Trials (1)

psyllium (1 trial)

Drugs in Phase 3 Trials (3)

blinatumomab (blincyto) (1 trial)

inactivated SARS-Cov-2 vaccine (1 trial)

methylprednisolone (medrol) (1 trial)

Drugs in Phase 2 Trials (4)

abemaciclib (verzenio) (1 trial)

albendazole (Albenza) (1 trial)

lorlatinib (lorbrena) (1 trial)

oxfendazole (2 trials)

Drugs in Other Trials (6)

niclosamide (nicloside) (1 trial)

propofol (diprivan) (1 trial)

sevoflurane (ultane) (1 trial)

teriparatide (1 trial)

unfractionated heparin (1 trial)

vitamin k (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Constipation (Phase 4)

Helminthiasis (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Neurocysticercosis (Phase 1)

Trichuriasis (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 14